Remove 2023 Remove Diagnostic Remove Disease Remove Nuclear Medicine
article thumbnail

Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

Imaging Technology

The Society introduced a new slate of officers, and recognized new Fellows, during its SNMMI 2023 Annual Meeting , held June 24-27 in Chicago, IL. The potential impact of nuclear medicine in the care of patients dealing with cancer, heart disease, brain disease, and other challenges is enormous,” she said. “We

article thumbnail

Research Showing Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease Presented at SNMMI 2023

Imaging Technology

Based on a novel clustering framework using sparse canonical correlation analysis (SCCA), the integrated approach was successful in identifying four subtypes of Alzheimer’s disease and the top genes associated with each, according to the authors of the study, “An SCCA-clustering framework for Alzheimer’s disease subtyping using tau PET and genomics.”

Disease 77
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

Imaging Technology

Due to their body shape, it’s often hard to image obese individuals,” said Krishna Patel, MD , assistant professor of medicine and cardiology at the Icahn School of Medicine At Mount Sinai in New York. This can result in inferior image quality and diagnostic performance despite requiring a higher dose of radiation.”

Disease 88
article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Thomas Hope, MD, a radiologist and nuclear medicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added.

article thumbnail

Whole-body PET/CT Predicts Response to HER2-targeted Therapy in Metastatic Breast Cancer Patients

Imaging Technology

milla1cf Wed, 10/11/2023 - 13:08 October 11, 2023 — A new imaging agent, 68Ga-ABY-025 , can predict early metabolic response to human epidermal growth factor receptor 2 ( HER2 )-targeted treatment in HER2-positive metastatic breast cancer patients, according to new research published in the September issue of The Journal of Nuclear Medicine.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.